• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血液透析剂量与特定病因死亡率的关系。

Relationship of dose of hemodialysis and cause-specific mortality.

作者信息

Bloembergen W E, Stannard D C, Port F K, Wolfe R A, Pugh J A, Jones C A, Greer J W, Golper T A, Held P J

机构信息

United States Renal Data System, University of Michigan, Ann Arbor, USA.

出版信息

Kidney Int. 1996 Aug;50(2):557-65. doi: 10.1038/ki.1996.349.

DOI:10.1038/ki.1996.349
PMID:8840286
Abstract

A number of studies have found a relationship of lower all-cause mortality risk for ESRD patients treated with increasing dose of dialysis. The objective of this study was to determine the relationship of delivered dose of dialysis with cause-specific mortality. Data from the USRDS Case Mix Adequacy Study, which includes a national random sample of hemodialysis patients, were utilized. To minimize the contribution of unmeasured residual renal function, the sample used in this analysis (N = 2479) included only patients on dialysis for one year or more. Cox proportional hazards models, stratified for diabetes, were used to analyze the effect of delivered dose of dialysis (measured and reported by both Kt/V and URR) on major causes of death and withdrawal from dialysis, adjusting for other covariates including demographics, comorbid diseases present at start of study, functional status, laboratory values and other dialysis parameters. Patient follow-up for mortality was censored at the earliest of time of transplantation, 60 days after a switch to peritoneal dialysis or at the time of data abstraction. For each 0.1 higher Kt/V, the adjusted relative risk of death due to coronary artery disease was 9% lower (RR = 0.91, P < 0.05), due to other cardiac causes was 12% lower (RR = 0.88, P < 0.01), due to cerebrovascular disease (CVD) was 14% lower (RR = 0.86, P < 0.05), due to infection was 9% lower (RR = 0.91, P = 0.05), and due to other known causes was 6% lower (RR = 0.94, P < 0.05). There was no statistically significant relationship of Kt/V and risk of death among patients who died of malignancy (RR = 0.84, P = 0.10) or among patients whose death cause was missing (RR = 0.95, P = 0.41). The risk of withdrawal from dialysis prior to death due to any cause was 9% lower (RR = 0.91, P < 0.05) for each 0.1 higher Kt/V. The relationships of delivered dose of dialysis, as measured by URR, and cause-specific mortality were essentially similar in relative magnitude and statistical significance as the relationships observed using Kt/V as the measurement of dialysis dose, with the exception that the relationship was less significant for cerebrovascular disease and withdrawal from dialysis. The relationship of dialysis dose with risk of death due to each cause of death category except other cardiac causes and "other" causes appeared to be of greater magnitude and of greater statistical significance among diabetics than non-diabetics. These results indicate that low dose of dialysis is not associated with mortality due to just one isolated cause of death, but rather is due to a number of the major causes of death in this population. This study is consistent with hypotheses that low doses of dialysis may promote atherogenesis, infection, malnutrition and failure to thrive through a variety of pathophysiologic mechanisms. Further study is necessary to confirm these results and to test hypotheses that are developed.

摘要

多项研究发现,接受透析剂量增加治疗的终末期肾病(ESRD)患者全因死亡风险较低。本研究的目的是确定透析的实际剂量与特定病因死亡率之间的关系。我们使用了美国肾脏数据系统(USRDS)病例组合充分性研究的数据,该研究包括全国血液透析患者的随机样本。为了尽量减少未测量的残余肾功能的影响,本分析中使用的样本(N = 2479)仅包括透析一年或更长时间的患者。采用针对糖尿病分层的Cox比例风险模型,分析透析的实际剂量(通过Kt/V和尿素清除率(URR)测量和报告)对主要死亡原因和透析退出的影响,并对其他协变量进行调整,包括人口统计学、研究开始时存在的合并疾病、功能状态、实验室值和其他透析参数。患者的死亡随访在移植时间、转为腹膜透析后60天或数据提取时间三者中最早的时间进行截尾。Kt/V每升高0.1,因冠状动脉疾病死亡的校正相对风险降低9%(风险比(RR)= 0.91,P < 0.05),因其他心脏原因死亡的校正相对风险降低12%(RR = 0.88,P < 0.01),因脑血管疾病(CVD)死亡的校正相对风险降低14%(RR = 0.86,P < 0.05),因感染死亡的校正相对风险降低9%(RR = 0.91,P = 0.05),因其他已知原因死亡的校正相对风险降低6%(RR = 0.94,P < 0.05)。在死于恶性肿瘤的患者中(RR = 0.84,P = 0.10)或死亡原因不明的患者中(RR = 0.95,P = 0.41),Kt/V与死亡风险之间无统计学显著关系。Kt/V每升高0.1,因任何原因在死亡前退出透析的风险降低9%(RR = 0.91,P < 0.05)。以URR衡量的透析实际剂量与特定病因死亡率之间的关系,在相对大小和统计学意义上与使用Kt/V作为透析剂量测量值时观察到的关系基本相似,唯一的例外是脑血管疾病和透析退出的关系不太显著。除其他心脏原因和“其他”原因外,透析剂量与各死亡原因类别导致的死亡风险之间的关系在糖尿病患者中似乎比非糖尿病患者更大且具有更大的统计学意义。这些结果表明,低剂量透析并非仅与某一孤立死亡原因导致的死亡率相关,而是与该人群中的多种主要死亡原因相关。本研究与以下假设一致,即低剂量透析可能通过多种病理生理机制促进动脉粥样硬化、感染、营养不良和生长发育不良。有必要进一步研究以证实这些结果并检验所提出的假设。

相似文献

1
Relationship of dose of hemodialysis and cause-specific mortality.血液透析剂量与特定病因死亡率的关系。
Kidney Int. 1996 Aug;50(2):557-65. doi: 10.1038/ki.1996.349.
2
Relationship of dialysis membrane and cause-specific mortality.透析膜与特定病因死亡率的关系。
Am J Kidney Dis. 1999 Jan;33(1):1-10. doi: 10.1016/s0272-6386(99)70251-9.
3
The dose of hemodialysis and patient mortality.血液透析剂量与患者死亡率。
Kidney Int. 1996 Aug;50(2):550-6. doi: 10.1038/ki.1996.348.
4
Risk factors for higher mortality at the highest levels of spKt/V in haemodialysis patients.血液透析患者中spKt/V最高水平时较高死亡率的危险因素。
Nephrol Dial Transplant. 2003 Jul;18(7):1339-44. doi: 10.1093/ndt/gfg162.
5
Association of Alternative Approaches to Normalizing Peritoneal Dialysis Clearance with Mortality and Technique Failure: A Retrospective Analysis Using the United States Renal Data System-Dialysis Morbidity and Mortality Study, Wave 2.腹膜透析清除率正常化的替代方法与死亡率和技术失败的关联:使用美国肾脏数据系统-透析发病率和死亡率研究第2波的回顾性分析
Perit Dial Int. 2017;37(1):85-93. doi: 10.3747/pdi.2015.00227. Epub 2016 Sep 28.
6
Normalized protein nitrogen appearance is correlated with hospitalization and mortality in hemodialysis patients with Kt/V greater than 1.20.标准化蛋白氮呈现与Kt/V大于1.20的血液透析患者的住院率及死亡率相关。
J Ren Nutr. 2003 Jan;13(1):15-25. doi: 10.1053/jren.2003.50005.
7
High dialysis dose is associated with lower mortality among women but not among men.高透析剂量与女性较低的死亡率相关,但与男性无关。
Am J Kidney Dis. 2004 Jun;43(6):1014-23. doi: 10.1053/j.ajkd.2004.02.014.
8
Exploring the reverse J-shaped curve between urea reduction ratio and mortality.探索尿素清除率与死亡率之间的反向J形曲线。
Kidney Int. 1999 Nov;56(5):1872-8. doi: 10.1046/j.1523-1755.1999.00734.x.
9
ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States.意大利伦巴第大区与美国终末期肾病患者合并症调整后的死亡率对比。
Kidney Int. 1996 Sep;50(3):1013-8. doi: 10.1038/ki.1996.403.
10
Body size, dialysis dose and death risk relationships among hemodialysis patients.血液透析患者的体型、透析剂量与死亡风险的关系
Kidney Int. 2002 Nov;62(5):1891-7. doi: 10.1046/j.1523-1755.2002.00642.x.

引用本文的文献

1
Sudden Cardiac Death Reporting in US Patients on Dialysis: Comparison of United States Renal Data System and National Death Index Data.美国透析患者的心源性猝死报告:美国肾脏数据系统与国家死亡索引数据的比较
Clin J Am Soc Nephrol. 2024 Dec 1;19(12):1613-1621. doi: 10.2215/CJN.0000000000000560. Epub 2024 Oct 15.
2
The association between dose of hemodialysis and patients mortality in a prospective cohort study.前瞻性队列研究中血液透析剂量与患者死亡率的关系。
Sci Rep. 2022 Aug 12;12(1):13708. doi: 10.1038/s41598-022-17943-0.
3
Executive summary of the Korean Society of Nephrology 2021 clinical practice guideline for optimal hemodialysis treatment.
韩国肾脏病学会 2021 年最佳血液透析治疗临床实践指南执行摘要。
Korean J Intern Med. 2022 Jul;37(4):701-718. doi: 10.3904/kjim.2021.543. Epub 2022 Jun 3.
4
Korean Society of Nephrology 2021 Clinical Practice Guideline for Optimal Hemodialysis Treatment.韩国肾脏病学会2021年最佳血液透析治疗临床实践指南。
Kidney Res Clin Pract. 2021 Dec;40(Suppl 1):S1-S37. doi: 10.23876/j.krcp.21.600. Epub 2021 Dec 10.
5
Executive Summary of the Korean Society of Nephrology 2021 Clinical Practice Guideline for Optimal Hemodialysis Treatment.韩国肾脏病学会2021年最佳血液透析治疗临床实践指南执行摘要
Kidney Res Clin Pract. 2021 Dec;40(4):578-595. doi: 10.23876/j.krcp.21.700. Epub 2021 Dec 10.
6
Dialysis Adequacy and Risk of Dementia in Elderly Hemodialysis Patients.老年血液透析患者的透析充分性与痴呆风险
Front Med (Lausanne). 2021 Nov 30;8:769490. doi: 10.3389/fmed.2021.769490. eCollection 2021.
7
The Association between Dialysis Dose and Risk of Cancer Death in Patients Undergoing Hemodialysis: The Q-Cohort Study.血液透析患者透析剂量与癌症死亡风险之间的关联:Q队列研究
Intern Med. 2020 May 1;59(9):1141-1148. doi: 10.2169/internalmedicine.4027-19. Epub 2020 Feb 12.
8
The impact of blood flow rate during hemodialysis on all-cause mortality.血液透析期间血流速度对全因死亡率的影响。
Korean J Intern Med. 2016 Nov;31(6):1131-1139. doi: 10.3904/kjim.2015.111. Epub 2016 Feb 22.
9
Bone mineral metabolism and subsequent hospitalization with poor quality of life in dialysis patients.透析患者的骨矿物质代谢及随后生活质量差导致的住院情况。
Nephrourol Mon. 2014 Jan 20;6(1):e14944. doi: 10.5812/numonthly.14944. eCollection 2014 Jan.
10
Computational study of the blood flow in three types of 3D hollow fiber membrane bundles.三种三维中空纤维膜束中血流的计算研究。
J Biomech Eng. 2013 Dec;135(12):121009. doi: 10.1115/1.4025717.